Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI)
Tuesday, February 07, 2023
Sensei Biotherapeutics announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to expand the development of SNS-101, a conditionally active, pH-selective VISTA-blocking antibody.
This collaborative between Sensei and the NCI further elucidates the role of VISTA in immune checkpoint resistance and expand the potential of SNS-101 as a combination therapy beyond anti-PD-1. Sensei expects to submit an Investigational New Drug (IND) application for SNS-101 in or before April 2023 and the trial is expected to commence thereafter in 2023, pending regulatory clearance.
This collaboration adds evidence that pH-selective VISTA inhibition can achieve a potentially different efficacy and safety profile, expand the rationale for combining VISTA inhibition with mechanisms other than PD-1 inhibition, and help us build a flow. SNS-101 clinical development plan.
